Meeting
2021 ASCO Quality Care Symposium
Biosimilar uptake of filgrastim and impact on spending in Medicare Part D from 2015 to 2019.
Authors
Syed Hussaini
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
Syed Hussaini, Arjun Gupta, Kelly E. Anderson, Jeromie M. Ballreich, Lauren H. Nicholas, Caleb Alexander
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cost, Value, and Policy; Health Equity and Disparities; Patient Experience
Track
Cost, Value, and Policy,Technology and Innovation in Quality of Care,Health Care Access, Equity, and Disparities,Patient Experience,Quality, Safety, and Implementation Science
Sub Track
Value/Cost of Care
Citation
J Clin Oncol 39, 2021 (suppl 28; abstr 67)
DOI
10.1200/JCO.2020.39.28_suppl.67
Abstract #
67
Poster Bd #
C6
Abstract Disclosures
Similar Posters
Poster
2018 Palliative and Supportive Care in Oncology Symposium
Potential Medicare beneficiary out-of-pocket cost reductions through use of biosimilar filgrastim-sndz over reference filgrastim among patients with lung cancer: A simulation model analysis.
First Author: Sanjeev Balu
Poster
2023 ASCO Annual Meeting
Biosimilar uptake and cost savings analysis before and after implementation of a pharmacist-driven substitution program within a National Community Oncology Network: One-year follow-up.
First Author: Melody Chang
Poster
2021 ASCO Annual Meeting
Patient factors associated with time to medication receipt of oral anti-cancer drugs.
First Author: Morgan RL Lichtenstein
Poster
2017 ASCO Quality Care Symposium
Off-label immunotherapy prescription: Financial implications for payers and patients.
First Author: Jonas A. De Souza